Logo

Microfluidics Firm Arradial Secures $3M in Additional Series A Financing

Apr 16, 2002

NEW YORK, April 16 - Arradial, a spin-off of Alexion Pharmaceuticals that develops microfluidic-based microarray technology, today said it has secured $3 million in additional Series A financing from Oxford Bioscience Partners.

 

The company, based in Bedford, Mass., is also expected to announce tomorrow the appointment of John R. Havens as senior vice president of technology. Havens, who comes to Arradial from Nanogen, where he was senior director for chemistry and high-throughput screening, will help the firm develop and commercialize its microfluidics technology.

 

Yesterday, Arradial hired Mark A. Tepper president and CEO. Tepper was previously vice president for research and operations at the Serono Pharmaceutical Research Institute.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.